📢Our 2025 Annual Report is here! 📢
In 2025, we awarded $43.4M in grant funding to leading researchers around the world. Learn more about how our grantees are advancing cancer diagnosis and treatment:
2025.themarkfoundation.org/
🚨Now accepting grant proposals!🚨
In partnership with @chordomafdn, we are launching the TBXT and Beyond ASPIRE Awards to accelerate novel therapeutic strategies targeting the chordoma surfaceome.
💵 Up to $500K over 24 months
🗓️ LOIs due: Dec 10
themarkfoundation.org/tbxt-a…
🧵👇
🔬 Open to independent investigators at non-profit research institutions worldwide. Co-investigators welcome.
Awardees will also be encouraged to leverage @chordomafdn’s suite of research-enabling tools and disease models to accelerate discovery.
For more details, eligibility requirements, and to start your application, view our full RFP: themarkfoundation.org/tbxt-a…
Congratulations to 2020 Emerging Leader Awardee Eliezer Van Allen on this exciting new role! 🎉
We’re pleased to share that Eliezer Van Allen, MD, of @VanAllenLab has been named our inaugural Chief Artificial Intelligence (AI) Officer (CAIO). Please join us in congratulating him on this new role.
We are incredibly proud to celebrate 8 members of @TheMarkFdn community newly elected to @theNAMedicine—one of the highest honors in health and medicine!👏🎉
themarkfoundation.org/blog/e…
The Mark Foundation for Cancer Research retweeted
We’re thrilled to announce a new joint grants program with @TheMarkFdn offering awards of up to $500K to help pave the way for chordoma patients to benefit from emerging treatment approaches that target cell surface proteins or peptides presented by MHC molecules on cancer cells. This is a major area of opportunity that builds on the results of several projects we’ve supported in recent years to identify surface targets.
Researchers: the request for proposals will open on Monday, October 26. More info: chordomafoundation.org/resea…
Thank you, @PatrickHwuMD, for your leadership and collaboration!
We need better therapies for #osteosarcoma, and that starts with bringing brilliant minds together. Grateful to @TheMarkFdn and @OSInstitute for convening such an outstanding group of investigators to challenge assumptions, spark new ideas and advance hope for patients who urgently need better treatments.
The Mark Foundation for Cancer Research retweeted
📢We're hiring! 📢
Join The Mark Foundation as a Scientific Director or Senior Scientific Director (depending on experience & qualifications) and help shape the future of cancer research. Learn more and apply:
themarkfoundation.org/scient…
#ScienceJobs #CancerResearch
We’re in CT for the 2026 Aging & Cancer Symposium, hosted by the Waxman Institute at The Mark Foundation (@WaxmanCancer) & @JacksonLab!
40+ attendees are exploring the frontier of aging biology & cancer, with topics ranging from cellular senescence to AI-driven risk prediction. 🔬
The Mark Foundation for Cancer Research retweeted
Thank you to @OSInstitute and @TheMarkFdn for the invitation this weekend at the IO summit for #osteosarcoma. Tremendous opportunity to identify opportunities for collaboration. I learned so much from you all. @PatrickHwuMD
We've had two thrilling days in Dallas gathering the scientific community for Advancing Immunotherapy for Osteosarcoma, organized with @OSInstitute. The challenges are immense, but so is the potential. Together, we're working toward better treatments for patients who urgently need them.
Great post from AITHYRA on one of our new Endeavor Award teams!
aithyra.at/news/detail/mark-…
Announcing $12M in new collaborative Endeavor Awards!
Our 4 new award teams span 11 institutions & 5 countries. Together, they are teaming up to tackle some of oncology's toughest challenges.
Read more: themarkfoundation.org/2026/1…
🧵👇
🔬Beating Immunotherapy Resistance
Immunotherapy fails most gastric cancer patients because tumors stop displaying the “flags” immune cells recognize.
@UNC & @MayoClinic scientists are targeting a specific cellular pathway to strip this invisibility cloak & restore immune attack.




















